This poster is published under an
open license. Please read the
disclaimer for further details.
Keywords:
Abdomen, Liver, MR physics, MR, MR-Diffusion/Perfusion, Diagnostic procedure, Imaging sequences, Staging, Cirrhosis, Metabolic disorders
Authors:
L. CUMINAL1, O. Beuf1, B. Leporq2, J. Dumortier1, S. Gaillard1, V. Hervieu1, O. Guillaud1, A. MULLER1, P.-J. Valette1; 1Lyon/FR, 2Villeurbanne/FR
DOI:
10.1594/ecr2016/B-1088
Methods and materials
Between September 2013 and June 2015,
55 patients (34 men and 21 women,
mean age: 50.6 years,
range: 22-80) with chronic liver disease were prospectively screened by biopsy and liver MRI.
Acquisitions were performed on a 3.0T MR750(GEHC) system.
The protocol included a set of routine sequences and innovative MRI technics which were already exposed and validate by Leporq et al.
:
1) SPGR multi-angle,
multi-echo sequence to quantify fat volume fraction (FVF),
a method including an estimation and correction of relaxation time effects,
accounting for the NMR spectrum of fat and resolving the dominant component ambiguity problem
2) Dynamic contrast enhanced 3D LAVA sequence with 1.8sec temporal resolution to calculate the hepatic Mean Transit Time (MTT),
perfusion index (HPI),
portal and arterial flows.
3) Intravoxel Incoherent Motion Imaging (IVIM) to calculate the pure molecular-based (Dslow) and perfusion related (Dfast) diffusion coefficient.
DICOM images from multiple gradient-echo,
IVIM and CE MRI were anonymized and transferred to CREATIS for image processing and quantification parameters using housed algorithm developed using Matlab.
Liver biopsy was performed the same day after the MRI by percutaneous sampling of the right lobe. All biopsies were fixed in formol and measured 7mm or more.
All the quantitative parameter values derived from MRI were compared to
semi-quantitative biopsy data (Brunt staging,
Fig. 1,
for steatosis and Ishak score for fibrosis,
Fig. 2 ) using area under the curve (AUC) and Spearman correlation coefficient (CorrS).